The Therapeutic use of human albumin in cancer patients' management.
Human albumin (HA) has been widely used in clinical practice due to its unique physiological characteristics and pharmacokinetics. However, with the absence of clear institutional recommendations, its uncontrolled prescription remains largely controversial. An extensive review on the albumin chemistry, pharmacology, physiology and pathology was performed, and data on commercially available HA, its cost, medical usage and the related available guidelines, particularly in oncology patients were gathered. Studies assessing the appropriate use and safety of HA in cancer patients are lacking. A retrospective survey of the appropriateness of HA infusions according to the SIMTI guidelines (2009) was performed in our department. Among 53 patients who received HA infusions, only 5.7% of the indications were appropriate for HA administration. Occasionally appropriate and inappropriate indications were considered in 10% and 84.3% of the prescriptions respectively with a relatively high cost. The adoption of strict guidelines may substantially reduce the inappropriate use and the subsequent healthcare costs.
['Moujaess|Elissar|E|', 'Fakhoury|May|M|', 'Assi|Tarek|T|', 'Elias|Hanine|H|', 'El Karak|Fadi|F|', 'Ghosn|Marwan|M|', 'Kattan|Joseph|J|']
D006801:Humans D009369:Neoplasms D016032:Randomized Controlled Trials as Topic D012189:Retrospective Studies D000075462:Serum Albumin, Human
Guidelines Human albumin infusion Hypoalbuminemia Medical oncology Survey of appropriate indication